<div id="readability-page-1"><p>Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) reached a new 52-week high on Monday . The company traded as high as $83.78 and last traded at $82.9950, with a volume of 160715 shares. The stock had previously closed at $81.77.</p><div><p><span></span><span>Get <strong>Tarsus Pharmaceuticals</strong> alerts:</span></p></div><h2>Analyst Ratings Changes</h2><ul><li>3 Biotech Catalysts Present Major Opportunity</li></ul><p>TARS has been the subject of several research reports. Mizuho began coverage on Tarsus Pharmaceuticals in a report on Thursday, November 20th. They set an &#34;outperform&#34; rating and a $100.00 price target for the company. HC Wainwright raised their target price on shares of Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the stock a &#34;neutral&#34; rating in a research note on Monday, October 20th. Guggenheim upped their price target on shares of Tarsus Pharmaceuticals from $84.00 to $87.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, November 5th. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Tarsus Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded Tarsus Pharmaceuticals from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Saturday, November 8th. Six investment analysts have rated the stock with a Buy rating, two have issued  a Hold rating and one  has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $74.14.</p><p><b>Check Out Our Latest Research Report on Tarsus Pharmaceuticals</b></p><h2>Tarsus Pharmaceuticals Price Performance</h2><p>The company has a fifty day simple moving average of $72.01 and a two-hundred day simple moving average of $55.67. The company has a debt-to-equity ratio of 0.22, a quick ratio of 4.25 and a current ratio of 4.29. The stock has a market capitalization of $3.49 billion, a price-to-earnings ratio of -40.71 and a beta of 0.74. </p><p>Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.05. The business had revenue of $118.70 million for the quarter, compared to analyst estimates of $114.22 million. Tarsus Pharmaceuticals had a negative net margin of 22.17% and a negative return on equity of 26.29%.  As a group, equities research analysts expect that  Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year. </p><h2>Insider Activity at Tarsus Pharmaceuticals</h2><p>In other news, CEO Bobak R. Azamian sold 6,000 shares of the firm's stock in a transaction that occurred on Wednesday, September 24th. The shares were sold at an average price of $55.37, for a total value of $332,220.00. Following the sale, the chief executive officer directly owned 812,106 shares in the company, valued at approximately $44,966,309.22. This trade represents a 0.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own  8.97% of the company's stock. </p><h2>Institutional Trading of Tarsus Pharmaceuticals</h2><p>Hedge funds and other institutional investors have recently modified their holdings of the stock. Allianz Asset Management GmbH bought a new stake in  Tarsus Pharmaceuticals during the 2nd quarter worth $227,000.  Lisanti Capital Growth LLC boosted its stake in shares of  Tarsus Pharmaceuticals by 7.6% during the second quarter. Lisanti Capital Growth LLC now owns 75,525 shares of the company's stock valued at $3,060,000 after purchasing an additional 5,345 shares in the last quarter.  Strs Ohio bought a new stake in shares of  Tarsus Pharmaceuticals during the first quarter worth about $288,000.  Adage Capital Partners GP L.L.C. acquired a new position in shares of  Tarsus Pharmaceuticals in the first quarter valued at approximately $26,199,000.  Finally, Campbell &amp; CO Investment Adviser LLC acquired a new position in shares of  Tarsus Pharmaceuticals in the second quarter valued at approximately $416,000. Institutional investors own  90.01% of the company's stock. </p><h2>About Tarsus Pharmaceuticals</h2> (Get Free Report)<p>Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.</p><h2>Read More</h2><ul><li>Five stocks we like better than Tarsus Pharmaceuticals</li><li>3 Natural Gas Stocks That Offer Great Dividend Yields</li><li>5 Tech Stocks Insiders Are Selling (But Smart Investors Are Loading Up)</li><li>Stock Dividend Cuts Happen Are You Ready?</li><li>Why FuelCell Energy Stock Is Soaring After a Government Deal</li><li>3 REITs to Buy and Hold for the Long Term</li><li>SoftBank’s Next AI Move? DigitalBridge Rockets 46% on Takeover Buzz</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Tarsus Pharmaceuticals Right Now?</h2><p>Before you consider Tarsus Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tarsus Pharmaceuticals wasn't on the list.</p><p>While Tarsus Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

TARS

<p>Tarsus Pharmaceuticals (NASDAQ:TARS) reached a new 52-week high, trading at $83.78. Analysts have given mixed ratings, with a consensus price target of $74.14. The company reported better-than-expected quarterly earnings, with revenue of $118.70 million. CEO Bobak Azamian sold shares, and institutional investors hold 90.01% of the stock. Tarsus focuses on eye care therapeutics, with its lead product XDEMVY targeting blepharitis.</p>

Tarsus Pharmaceuticals (NASDAQ:TARS) Sets New 12-Month High - Here's What Happened